Despite widespread popular interest in the use of low doses of Lysergic acid diethylamide (LSD) to improve mood, little is known about how these doses affect emotional processing in the brain. In this study, we tested the effect of a single low dose of LSD (26 µg) compared with placebo on electroencephalogram (EEG) event-related potentials (ERP: N170, P300 and Mismatch Negativity) in healthy adults, while participants viewed angry, happy, and neutral faces. We hypothesized that the drug might affect either neutral faces, which are sometimes perceived as threatening, or emotional faces.
Methods:
Healthy young adults (n = 39) received LSD (26 µg or placebo sublingually) before completing an oddball task with emotional facial expressions during EEG recording. The N170 and P300 evoked potentials were recorded using EEG. LSD and placebo were administered in double-blind, randomized order separated by at least 7 days. During the oddball task, three emotional faces were presented infrequently (angry, happy, neutral) in a block design, and a cartoon face was presented frequently.
Results:
LSD significantly reduced the amplitude of the occipitotemporal N170 ERP to Neutral faces, but not angry or happy faces. LSD also reduced the amplitude of the midline posterior parietal P300 ERP to neutral and happy faces, but not angry faces.
Discussion:
These differential effects of LSD on the amplitude of the N170 and P300 to neutral and emotional faces add to our understanding of how low doses of LSD might affect the brain response to social and emotional information.
Get full access to this article
View all access options for this article.
References
1.
ShawE, WoolleyDW. Some serotoninlike activities of lysergic acid diethylamide. Science, 1956; 124(3212):121–122; doi: 10.1126/science.124.3212.121
2.
FreedmanDX. Effects of LSD-25 on brain serotonin. J Pharmacol Exp Ther, 1961; 134:160–166.
3.
InserraA, De GregorioD, GobbiG. Psychedelics in psychiatry: Neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharmacol Rev, 2021; 73(1):202–277; doi: 10.1124/pharmrev.120.000056
4.
KwanAC, OlsonDE, PrellerKH, et al.The neural basis of psychedelic action. Nat Neurosci, 2022; 25(11):1407–1419; doi: 10.1038/s41593-022-01177-4
5.
PolitoV, LiknaitzkyP. The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field. Neurosci Biobehav Rev, 2022; 139:104706; doi: 10.1016/j.neubiorev.2022.104706
6.
HuttenNRPW, MasonNL, DolderPC, et al.Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study. Eur Neuropsychopharmacol, 2020; 41:81–91; doi: 10.1016/j.euroneuro.2020.10.002
7.
SzigetiB, KartnerL, BlemingsA, et al.Self-blinding citizen science to explore psychedelic microdosing. Elife, 2021; 10:10; doi: 10.7554/eLife.62878
8.
BershadAK, SchepersST, BremmerMP, et al.Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. Biol Psychiatry, 2019; 86(10):792–800; doi: 10.1016/j.biopsych.2019.05.019
9.
de WitH, MollaHM, BershadA, et al.Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response Study. Addict Biol, 2022; 27(2):e13143; doi: 10.1111/adb.13143
10.
HolzeF, LiechtiME, HuttenNRPW, et al.Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants. Clin Pharmacol Ther, 2021; 109(3):658–666; doi: 10.1002/cpt.2057
11.
MurphyRJ, SumnerR, EvansW, et al.Acute mood-elevating properties of microdosed lysergic acid diethylamide in healthy volunteers: A home-administered randomized controlled trial. Biol Psychiatry, 2023; 94(6):511–521; doi: 10.1016/j.biopsych.2023.03.013
12.
BershadAK, PrellerKH, LeeR, et al.Preliminary report on the effects of a low dose of LSD on resting-state amygdala functional connectivity. Biol Psychiatry Cogn Neurosci Neuroimaging, 2020; 5(4):461–467; doi: 10.1016/j.bpsc.2019.12.007
13.
GlazerJ, MurrayCH, NusslockR, et al.Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity. Neuropsychopharmacology, 2023; 48(2):418–426; doi: 10.1038/s41386-022-01479-y
14.
HuttenNRPW, MasonNL, DolderPC, et al.Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers. ACS Pharmacol Transl Sci, 2020; 4(2):461–466; doi: 10.1021/acsptsci.0c00099
15.
VargasMV, DunlapLE, DongC, et al.Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science, 2023; 379(6633):700–706; doi: 10.1126/science.adf0435
16.
DolderPC, SchmidY, MüllerF, et al.LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology, 2016; 41(11):2638–2646; doi: 10.1038/npp.2016.82
17.
BernasconiF, SchmidtA, PokornyT, et al.Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin. Cereb Cortex, 2014; 24(12):3221–3231; doi: 10.1093/cercor/bht178
18.
KometerM, SchmidtA, BachmannR, et al.Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry, 2012; 72(11):898–906; doi: 10.1016/j.biopsych.2012.04.005
19.
BorraD, BossiF, RivoltaD, et al.Deep learning applied to EEG source-data reveals both ventral and dorsal visual stream involvement in holistic processing of social stimuli. Sci Rep, 2023; 13(1):7365; doi: 10.1038/s41598-023-34487-z
20.
EimerM, HolmesA. Event-related brain potential correlates of emotional face processing. Neuropsychologia, 2007; 45(1):15–31; doi: 10.1016/j.neuropsychologia.2006.04.022
21.
KanwisherN, YovelG. The fusiform face area: A cortical region specialized for the perception of faces. Philos Trans R Soc Lond B Biol Sci, 2006; 361(1476):2109–2128; doi: 10.1098/rstb.2006.1934
22.
JinH, HaywardWG, CorballisPM. All-or-none neural mechanisms underlying face categorization: Evidence from the N170. Cereb Cortex, 2022; 33(3):777–793; doi: 10.1093/cercor/bhac101
23.
BlauVC, MaurerU, TottenhamN, et al.The face-specific N170 component is modulated by emotional facial expression. Behav Brain Funct, 2007; 3:7–7; doi: 10.1186/1744-9081-3-7
24.
HietanenJK, AstikainenP. N170 response to facial expressions is modulated by the affective congruency between the emotional expression and preceding affective picture. Biol Psychol, 2013; 92(2):114–124; doi: 10.1016/j.biopsycho.2012.10.005
25.
DonchinE, ColesMGH. Is the P300 component a manifestation of context updating? Behav Brain Sci, 1988; 11(03):357–374; doi: 10.1017/S0140525X00058027
26.
HajcakG, DunningJP, FotiD. Motivated and controlled attention to emotion: Time-course of the late positive potential. Clin Neurophysiol, 2009; 120(3):505–510; doi: 10.1016/j.clinph.2008.11.028
27.
RischerKM, SavallampiM, AkwaththageA, et al.In context: Emotional intent and temporal immediacy of contextual descriptions modulate affective ERP components to facial expressions. Soc Cogn Affect Neurosci, 2020; 15(5):551–560; doi: 10.1093/scan/nsaa071
28.
GarridoMI, KilnerJM, StephanKE, et al.The mismatch negativity: A review of underlying mechanisms. Clin Neurophysiol, 2009; 120(3):453–463; doi: 10.1016/j.clinph.2008.11.029
29.
TimmermannC, SpriggsMJ, KaelenM, et al.LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm. Neuropharmacology, 2018; 142:251–262; doi: 10.1016/j.neuropharm.2017.10.039
30.
KometerM, SchmidtA, JänckeL, et al.Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci, 2013; 33(25):10544–10551; doi: 10.1523/JNEUROSCI.3007-12.2013
31.
SchmidtA, KometerM, BachmannR, et al.The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacology (Berl), 2013; 225(1):227–239; doi: 10.1007/s00213-012-2811-0
32.
BravermanováA, ViktorinováM, TylšF, et al.Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers. Psychopharmacology (Berl), 2018; 235(2):491–503; doi: 10.1007/s00213-017-4807-2
33.
MurrayCH, TareI, PerryCM, et al.Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults. Psychopharmacology (Berl), 2022; 239(6):1735–1747; doi: 10.1007/s00213-021-05991-9
34.
KleinF, IfflandB, SchindlerS, et al.This person is saying bad things about you: The influence of physically and socially threatening context information on the processing of inherently neutral faces. Cogn Affect Behav Neurosci, 2015; 15(4):736–748; doi: 10.3758/s13415-015-0361-8
35.
MoreanME, De WitH, KingAC, et al.The drug effects questionnaire: Psychometric support across three drug types. Psychopharmacology (Berl), 2013; 227(1):177–192; doi: 10.1007/s00213-012-2954-z
36.
DittrichA. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry, 1998; 31(Suppl 2):80–84; doi: 10.1055/s-2007-979351
37.
DelormeA, MakeigS. EEGLAB: An open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. J Neurosci Methods, 2004; 134(1):9–21; doi: 10.1016/j.jneumeth.2003.10.009
38.
Bigdely-ShamloN, MullenT, KotheC, et al.The PREP pipeline: Standardized preprocessing for large-scale EEG analysis. Front Neuroinform, 2015; 9:16; doi: 10.3389/fninf.2015.00016
39.
AblinP, CardosoJ-F, GramfortA. Faster independent component analysis by preconditioning with hessian approximations. IEEE Trans Signal Process, 2018; 66(15):4040–4049; doi: 10.1109/TSP.2018.2844203
40.
RazS, DanO. Altered event-related potentials in adults with ADHD during emotional faces processing. Clin Neurophysiol, 2015; 126(3):514–523; doi: 10.1016/j.clinph.2014.06.023
41.
TottenhamN, TanakaJW, LeonAC, et al.The NimStim set of facial expressions: Judgments from untrained research participants. Psychiatry Res, 2009; 168(3):242–249; doi: 10.1016/j.psychres.2008.05.006
JacquesC, JonasJ, MaillardL, et al.The inferior occipital gyrus is a major cortical source of the face-evoked N170: Evidence from simultaneous scalp and intracerebral human recordings. Hum Brain Mapp, 2019; 40(5):1403–1418; doi: 10.1002/hbm.24455
44.
AlmeidaPR, Ferreira-SantosF, ChavesPL, et al.Perceived arousal of facial expressions of emotion modulates the N170, regardless of emotional category: Time domain and time-frequency dynamics. Int J Psychophysiol, 2016; 99:48–56; doi: 10.1016/j.ijpsycho.2015.11.017
45.
HinojosaJA, MercadoF, CarretiéL. N170 sensitivity to facial expression: A meta-analysis. Neurosci Biobehav Rev, 2015; 55:498–509; doi: 10.1016/j.neubiorev.2015.06.002
46.
FitzgeraldDA, AngstadtM, JelsoneLM, et al.Beyond threat: Amygdala reactivity across multiple expressions of facial affect. Neuroimage, 2006; 30(4):1441–1448; doi: 10.1016/j.neuroimage.2005.11.003
47.
Brodski-GuernieroA, PaaschG-F, WollstadtP, et al.Information-theoretic evidence for predictive coding in the face-processing system. J Neurosci, 2017; 37(34):8273–8283; doi: 10.1523/JNEUROSCI.0614-17.2017
48.
BrotmanMA, RichBA, GuyerAE, et al.Amygdala activation during emotion processing of neutral faces in children with severe mood dysregulation versus ADHD or bipolar disorder. Am J Psychiatry, 2010; 167(1):61–69; doi: 10.1176/appi.ajp.2009.09010043
49.
DenefrioS, MyruskiS, MenninD, et al.When neutral is not neutral: Neurophysiological evidence for reduced discrimination between aversive and non-aversive information in generalized anxiety disorder. Motiv Emot, 2019; 43(2):325–338; doi: 10.1007/s11031-018-9732-0
50.
PfaltzMC, PassardiS, AuschraB, et al.Are you angry at me? Negative interpretations of neutral facial expressions are linked to child maltreatment but not to posttraumatic stress disorder. Eur J Psychotraumatol, 2019; 10(1):1682929; doi: 10.1080/20008198.2019.1682929
51.
WregeJS, RuoccoAC, CarconeD, et al.Facial emotion perception in borderline personality disorder: Differential neural activation to ambiguous and threatening expressions and links to impairments in self and interpersonal functioning. J Affect Disord, 2021; 284:126–135; doi: 10.1016/j.jad.2021.01.042
52.
YoonKL, ZinbargRE. Interpreting neutral faces as threatening is a default mode for socially anxious individuals. J Abnorm Psychol, 2008; 117(3):680–685; doi: 10.1037/0021-843X.117.3.680
53.
WackerD, WangS, McCorvyJD, et al.Crystal structure of an LSD-bound human serotonin receptor. Cell, 2017; 168(3):377–389.e12; doi: 10.1016/j.cell.2016.12.033
54.
KimK, CheT, PanovaO, et al.Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor. Cell, 2020; 182(6):1574–1588.e19; doi: 10.1016/j.cell.2020.08.024
55.
KraehenmannR, PrellerKH, ScheideggerM, et al.Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry, 2015; 78(8):572–581; doi: 10.1016/j.biopsych.2014.04.010
56.
BentinS, AllisonT, PuceA, et al.Electrophysiological studies of face perception in humans. J Cogn Neurosci, 1996; 8(6):551–565; doi: 10.1162/jocn.1996.8.6.551
57.
PolichJ. Updating P300: An integrative theory of P3a and P3b. Clin Neurophysiol, 2007; 118(10):2128–2148; doi: 10.1016/j.clinph.2007.04.019
58.
ShahD, KnottV, BaddeleyA, et al.Impairments of emotional face processing in schizophrenia patients: Evidence from P100, N170 and P300 ERP components in a sample of auditory hallucinators. Int J Psychophysiol, 2018; 134:120–134; doi: 10.1016/j.ijpsycho.2018.10.001
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
